renalytix ai plc (lse aim: renx) is a leading developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. the company’s solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. renalytixai’s initial diagnostic product, kidneyintelx™, is designed to diagnose and improve clinical management of patients with type ii diabetes and those of african ancestry with fast-progressing kidney disease in an effort to curtail the estimated $114 billion cost of chronic and end-stage kidney disease to the u.s. healthcare system. renalytixai expects to commercially launch kidneyintelx as a laboratory developed test in its clia laboratory facilities to health systems and drug developers in h2 2019. the company also intends to submit kidneyintelx for regulatory rev
![Renalytix logo](/files/LOGO/1811115-RNLX.png)
Company profile
Ticker
RTNXF, RNLX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Renalytix AI plc
SEC CIK
Corporate docs
Subsidiaries
Renalytix AI, Inc. • Renalytix AI Limited ...
RTNXF stock data
Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
27 Aug 24
8-K
Issue of Shares and Rule 2.9 Announcement
15 Jul 24
EFFECT
Notice of effectiveness
1 Jul 24
424B3
Prospectus supplement
28 Jun 24
S-3/A
Shelf registration (amended)
25 Jun 24
8-K/A
Changes in Registrant's Certifying Accountant
25 Jun 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
24 Jun 24
8-K
Changes in Registrant's Certifying Accountant
24 Jun 24
8-K
Regulation FD Disclosure
17 Jun 24
S-3/A
Shelf registration (amended)
14 Jun 24
Transcripts
RTNXF
Earnings call transcript
2024 Q3
15 May 24
RTNXF
Earnings call transcript
2024 Q1
14 Nov 23
RTNXF
Earnings call transcript
2023 Q3
9 Jun 23
RTNXF
Earnings call transcript
2023 Q3
9 Jun 23
RTNXF
Earnings call transcript
2023 Q2
30 Mar 23
RTNXF
Earnings call transcript
2023 Q2
30 Mar 23
RTNXF
Earnings call transcript
2023 Q1
30 Nov 22
RTNXF
Earnings call transcript
2023 Q1
30 Nov 22
RTNXF
Earnings call transcript
2022 Q4
31 Oct 22
RTNXF
Earnings call transcript
2022 Q4
31 Oct 22
Latest ownership filings
4
Joel R Jung
13 Jun 24
3
Joel R Jung
5 Jun 24
4
SCHOOL OF MEDICINE AT MOUNT SINAI ICAHN
26 Apr 24
SC 13D/A
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
26 Apr 24
SC 13G
CVI Investments, Inc.
4 Apr 24
SC 13D/A
JEFFERSON RIVER CAPITAL LLC
21 Mar 24
4
Catherine Coste
22 Nov 23
4
DANIEL J LEVANGIE
22 Nov 23
4
Chirag R. Parikh
22 Nov 23
4
CHRISTOPHER MILLS
22 Nov 23
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.70 mm | 4.70 mm | 4.70 mm | 4.70 mm | 4.70 mm | 4.70 mm |
Cash burn (monthly) | 305.00 k | 3.05 mm | 2.58 mm | 3.14 mm | 1.62 mm | 2.58 mm |
Cash used (since last report) | 1.54 mm | 15.40 mm | 13.02 mm | 15.83 mm | 8.18 mm | 13.00 mm |
Cash remaining | 3.16 mm | -10.70 mm | -8.32 mm | -11.12 mm | -3.47 mm | -8.30 mm |
Runway (months of cash) | 10.4 | -3.5 | -3.2 | -3.5 | -2.1 | -3.2 |
Institutional ownership, Q2 2024
13F holders | Current |
---|---|
Total holders | 28 |
Opened positions | 22 |
Closed positions | 0 |
Increased positions | 2 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 784.53 mm |
Total shares | 243.29 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
School Of Medicine At Mount Sinai Icahn | 222.87 mm | $0.00 |
CVI Investments | 8.55 mm | $7.35 mm |
Jefferson River Capital | 8.53 mm | $8.53 mm |
Pinnacle Associates | 815.43 k | $188.36 mm |
SF Stifel Financial | 561.00 k | $129.59 mm |
Levin Capital Strategies | 555.00 k | $128.21 mm |
Tejara Capital | 500.39 k | $115.59 mm |
CI Private Wealth | 335.51 k | $77.50 mm |
Nantahala Capital Management | 117.64 k | $27.18 mm |
Cantor Fitzgerald, L. P. | 115.00 k | $26.57 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Jun 24 | Joel R Jung | Employee Stock Option Ordinary Shares | Grant | Acquire A | No | No | 0.2067 | 60,000 | 12.40 k | 60,000 |
24 Apr 24 | School Of Medicine At Mount Sinai Icahn | Ordinary Shares | Other | Acquire J | No | No | 0.25 | 9,360,374 | 2.34 mm | 19,317,248 |
20 Nov 23 | Howard Doran JR | Employee Stock Option Ordinary Shares | Grant | Acquire A | No | No | 0.304 | 300,000 | 91.20 k | 300,000 |
20 Nov 23 | Chirag R. Parikh | Employee Stock Option Ordinary Shares | Grant | Acquire A | No | No | 0.304 | 95,000 | 28.88 k | 95,000 |
News
Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
29 Jul 24
HC Wainwright & Co. Reiterates Buy on Renalytix, Maintains $3 Price Target
12 Jul 24
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
12 Jul 24
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
11 Jul 24
Nasdaq Dips Over 300 Points; PepsiCo Reports Weak Sales
11 Jul 24